Research on Clinical Recovery and Maintenance Strategies for CHB
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorBeijing Municipal Administration of Hospitals
About this trial
Collect basic information of patients before antiviral treatment and when HBsAg disappears, and divide them into three groups A, B, and C based on baseline anti HBs titers after informed consent. During the follow-up period of all patients, clinical biochemistry, virology (HBVDNA, HBVRNA), serological indicators (HBsAg, anti HBs, HBeAg, anti HBe, HBcrAg, anti HBc), AFP, Fibroscan, liver imaging examinations will be conducted every 3-6 months, and blood samples will be retained for monitoring the frequency of immune cells (pDC, Treg) and the expression of functional molecules, as well as cytokines (IFN - γ, IP-10, IL-10, and TGF - β). Observe the sustained response rate and recurrence rate of virological and serological indicators, as well as the incidence of hepatitis and liver cancer during the follow-up period.
Eligibility criteria
Qualifiers
Age between 18 and 65 years old;
Gender is not limited;
CHB patients who meet the diagnostic criteria of the 2019 edition of the Guidelines for the Prevention and Treatment of Chronic Hepatitis B [5];
Confirmed interferon treatment resulted in HBsAg disappearance, HBeAg negativity, and HBV DNA below the lower detection limit and cessation Patients treated with interferon;
Disqualifiers
Merge with other hepatitis virus (HCV, HDV) infections;
Autoimmune liver disease;
HIV infection;
Long term alcohol abuse and/or other liver damaging drugs;
Trial design
Treatments tested in this trial
- baseline anti-HBs titer
Treatment groups
285 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov